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Abstract
Background: Clostridium difficile-associated disease (CDAD) is a serious nosocomial infection,
however few studies have assessed CDAD outcome in the intensive care unit (ICU). We evaluated
the epidemiology, clinical course and outcome of hospital-acquired CDAD in the critical care
setting.
Methods: We performed a historical cohort study on 58 adults with a positive C. difficile cytotoxin
assay result occurring in intensive care units.
Results: Sixty-two percent of patients had concurrent infections, 50% of which were bloodstream
infections. The most frequently prescribed antimicrobials prior to CDAD were anti-anaerobic
agents (60.3%). Septic shock occurred in 32.8% of CDAD patients. The in-hospital mortality was
27.6%. Univariate analysis revealed that SOFA score, at least one organ failure and age were
predictors of mortality. Charlson score ≥3, gender, concurrent infection, and number of days with
diarrhea before a positive C. difficile toxin assay were not significant predictors of mortality on
univariate analysis. Independent predictors for death were SOFA score at infection onset (per 1point increment, OR 1.40; CI95 1.13–1.75) and age (per 1-year increment, OR 1.10; CI95 1.02–
1.19).
Conclusion: In ICU patients with CDAD, advanced age and increased severity of illness at the
onset of infection, as measured by the SOFA score, are independent predictors of death.

Background
Clostridium difficile is a major cause of antibiotic associated diarrhea and colitis [1]. The incidence of infection
with this organism is increasing in hospitals worldwide,
consequent to the widespread use of broad-spectrum antibiotics [2].

Hospital-acquired C. difficile disease is associated with not
only antimicrobial use, but also advanced age, laxative
use, proton pump inhibitors, antineoplastic chemotherapeutic agent use, renal insufficiency, and gastrointestinal
surgery or procedures [3,4].
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Over the past several years, numerous reports have been
published regarding CDAD in immunocompromised
patients (bone marrow transplantation, solid organ transplantation, HIV infected patients and those with neutropenia), [5-9] as well as hospitalized patients in acute care
medical wards [10].
The clinical and financial impact of nosocomial CDAD, as
measured by the attributable cost and length of stay, is significant [11]. However few studies have assessed CDAD
outcome in the intensive care unit (ICU) setting [12].
The purpose of this study was to evaluate the epidemiology, clinical course and outcome of hospital-acquired
CDAD in the ICU setting.

Methods
Setting
The Virginia Commonwealth University Medical Center
(VCUMC) is an 820-bed tertiary care facility in Richmond,
Virginia. The hospital houses 9 intensive care units
(ICUs), including pediatric ICUs and a burn unit. Approximately 30,000 patients are admitted annually. The study
was approved by the VCUMC Institutional Review Board
(IRB).
Study design
All ICU patients with a positive C. difficile toxin at VCU
Medical Center from January 2002 to August 2005 were
identified retrospectively using the electronic medical
microbiology record. This was followed by a retrospective
chart review. Each patient was only included once at the
time of the first C. difficile result. Patients older than 18
years of age were included in the analysis. At study entry,
we recorded patient age, gender, location (medical ICU or
surgical ICU), predisposing clinical conditions on admission, and colonoscopy or surgical procedures for CDAD.
Data on nosocomial infections were collected for 14 days
following the date of the first positive C. difficile toxin
result. Additionally, we collected data on the duration of
diarrhea before and after diagnosis and treatment of
CDAD. Antimicrobial exposure preceding the diagnosis of
CDAD and the interruption of antimicrobial treatment
due to CDAD were also collected. Colonization status
with methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) were identified by clinical
cultures during the time of study. Adverse outcomes
(organ failure and mortality) that occurred during the
hospital stay were recorded. The clinical condition of each
patient was classified daily according to systemic inflammatory response syndrome (SIRS) criteria [SIRS, sepsis,
severe sepsis or septic shock] and SOFA scores from two
days prior to the first positive stool C. difficile-toxin assay
through 14 days afterwards [13,14]. The Sequential Organ
Failure Assessment (SOFA) score, assesses the incidence
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and severity of organ dysfunction in critically ill patients
[14]. The severity of underlying disease preceding CDAD
was classified using the Charlson weighted comorbidity
index [15].
Definitions
We defined a CDAD case as a patient with a positive stool
C. difficile cytotoxin assay result and diarrhea. Diarrhea
was defined as a change in bowel habit with ≥3 unformed
bowel movements per day for ≥2 days [10]. We defined
treatment failure as recurrence of diarrhea plus an additional stool specimen positive for C. difficile toxin or a
physician order for a second course of treatment for C. difficile. Concurrent infection detected during CDAD was
defined according to Centers for Disease Control and Prevention (CDC) criteria [16]. P revious antibiotic treatment
was defined as an antibiotic prescribed for at least 48
hours in the 60 days prior to CDAD. The SOFA score was
used to assess disease severity [14]. Systemic Inflammatory Response Syndrome (SIRS) was defined as two or
more of the following: (1) temperature >38°C or <36°C,
(2) heart rate >90 beats per minute, (3) respiratory rate
>20 breaths per minute or a PaCO2 <32 mmHg, or (4)
white blood cell count >12 × 109/L or <4 × 109/L or the
presence of more than 10% immature neutrophils.

The clinical condition of each patient with CDAD was
classified daily as SIRS, sepsis, severe sepsis or septic shock
using criteria previously published by the American College of Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM) [13]. Sepsis was defined as SIRS associated
with C. difficile-associated diarrhea. Sepsis associated with
organ dysfunction, hypotension or systemic manifestations of hypoperfusion constituted severe sepsis. Septic
shock was defined as sepsis associated with hypotension
unresponsive to intravenous fluid challenge or the need
for a vasopressor agent. The presence of organ system failure was assessed using the criteria described by Fagon
[17]. Nosocomial infection was defined as an infection
that occurred >48 hours after hospital admission, an
infection that occurred <48 hours after admission to the
hospital in patients that had been hospitalized in the 3
weeks prior to the admission, or an infection that
occurred <48 hours after admission to the hospital in
patients that had been transferred from another hospital
or nursing home [16]. Treatment for CDAD was defined
as the receipt of metronidazole at a dosage of 250 mg 4
times per day or 500 mg 3 times per day for 10–14 days,
or oral vancomycin 125 mg 4 times per day for the same
duration.
Statistical analysis
Continuous variables were compared using the Student t
test for normally distributed variables and the MannWhitney U test for non-normally distributed variables.
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Differences in proportions were compared using a Chisquare test or Fisher exact test when appropriate. Alpha
was set at 0.05 and all tests of significance were two-tailed.
Variables significant for predicting mortality in univariate
analysis were entered into a logistic regression model.
When collinearity was identified between two variables in
a correlation matrix, the one with the greatest clinical relevance associated with mortality was included in the final
multivariate analysis. The Hosmer and Lemeshow goodness-of-fit statistic was used to assess adequacy of the
model fit. Odds ratios with 95% confidence intervals were
calculated for independent variables associated with mortality related to CDAD. All statistical analyses were done
using the Statistical Package for the Social Sciences software (SPSS version 11.0, Chicago, IL, USA).

Results
Study population and patient characteristics. From 613
hospitalized patients with CDAD, a total of 70 patients
were identified at VCUMC ICUs during the study period.
Sixty-three patients (90%) were adults and 7 were pediatric patients (10%). Of the adult patients, 5 (7.9%) had
incomplete medical records. The remaining 58 adult ICU
patients with CDAD were included in the analysis.
The median age was 55.5 years with an inter-quartile
range (IQR) from 43 to 64 years. Twenty-two patients
(37.9%) were over 60 years of age. The majority of
patients were from surgical ICUs (63.8%). The most frequent admission diagnoses were trauma (22.4%), cardiovascular disease (20.7%), gastrointestinal diseases
(17.2%) and solid and haematologic malignancies
(12.1%). The mean interval between hospitalization and
CDAD infection was 16.8 ± 18.5 days. The median duration of hospitalization was 32.0 days (IQR = 16.7–68.2).
The mean duration of diarrhea before CDAD diagnosis
was 6.5 ± 7.0 days. The majority of patients (93.1%) were
receiving antimicrobial therapy before CDAD (Table 1).
The most frequently prescribed antimicrobials prior to
CDAD were anti-anaerobic agents considering piperacillin-tazobactam, metronidazole, carbapenems, or clindamycin (60.3%), quinolones (43.1%), and intravenous
vancomycin (43.1%). Other prescribed antimicrobials
were also cephalosporins (36.2%) and aminoglycosides
(15.6%).
Sixty-two percent of patients (36/58) had a concurrent
infection; of these 50% (18/36) were bloodstream infections (BSIs), a sizable fraction of which (39.9%, 11/18)
were polymicrobial. The most frequent concurrent BSI
pathogens BSI were gram-negative bacteria (35.0%), following by coagulase-negative staphylococci (20.0%), and
Candida albicans (20.0%). Other isolated pathogens Enterococcus spp (15.0%), Streptococcus viridans (5.0%) and
Candida glabrata (5.0%). No vancomycin-resistant entero-
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Table 1: Characteristics of CDAD in ICU patients.

VARIABLES
Age, years
Median (IQR)
≤65
>65
Male gender
Charlson index, median (range)
Intensive care unit
Medical
Surgical
Diagnosis on admission
Trauma
Cardiovascular disease
Gastrointestinal disease
Neoplasm
Respiratory disease
Neurologic disease
Other
Interval between hospitalization and
CDAD, mean days ± SD
Length of hospital stay: median days
(IQR)
Days with diarrhea before positive C.
difficile toxin assay, mean ± SD (range)
Received antimicrobial therapy prior
to CDAD
Concomitant infection
Initial antibiotic treatment course
Metronidazole
None
Second antibiotic treatment course
Not required
Metronidazole
Vancomycin
Metronidazole and vancomycin
Continued to receive antimicrobial
therapy after CDAD
Concurrent MRSA or VRE colonization
In-hospital mortality

N

%

55.5 (43.0–64.0)
47
11
35
2 (0–8)

81.0
19.0
60.3
-

21
37

36.2
63.8

13
12
10
7
6
4
6
16.8 ± 18.5

22.4
20.7
17.2
12.1
10.3
6.9
10.3
-

32.0 (16.7–68.2)

-

6.5 ± 7.0 (0–31)

-

54

93.1

36

62.1

57
1

98.3
1.7

53
2
1
2
49

91.4
3.4
1.7
3.4
84.5

18
16

31.0
27.6

cocci were detected. In approximately thirty-nine percent
of BSI patients (7/18), a 24 hours delay in the initiation of
appropriate antimicrobial therapy was observed.
Nearly all patients (98.3%) with CDAD received metronidazole as the initial antimicrobial treatment. Five
patients failed the first course of antimicrobial therapy
(8.6%); of these, two were treated with a second course of
metronidazole, one was treated with vancomycin and two
patients received both drugs (Table 1). The majority of
patients (84.5%) with CDAD received concurrent antimicrobial therapy; in 13 (22.4%) of these patients there was
no evidence of another infection. Two patients (3.4%)
underwent colonoscopy for CDAD, but no patients
required operative management. Almost one-third of
CDAD patients were colonized with MRSA or VRE
(31.0%).
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Clinical course
Septic shock occurred in 32.8% (19/58) of CDAD
patients. The maximal SIR (severe sepsis, septic shock or
death) occurred in 43.1% (25/58) during the 14 days following the first positive C. difficile toxin assay. No significant difference was observed in maximal SIR score
between patients with CDAD only and those with concurrent nosocomial infection (31.8% vs. 50.0%, p = 0.17). A
statistically significant difference in SOFA scores was
observed between the survivors and non-survivors. The
14-day mortality was 17.2% (10/58) and the in-hospital
mortality was 27.6% (16/58).

Univariate analysis revealed that SOFA score, septic shock,
at least one organ failure (respiratory, cardiovascular,
renal, hematologic and hepatic) and age were significant
predictors of mortality (table 2). Charlson score ≥3, gender, other concurrent nosocomial infections, and days
from start of diarrhea to start of treatment for CDAD were
not significant predictors of mortality on univariate analysis. Variables significant for predicting mortality in univariate analysis (age, SOFA score and at least one organ
failure) were entered into a logistic regression model (p <
0.05). Using this model, the following variables were
independent predictors for death (table 3): SOFA score at
CDAD infection onset (per 1-point increment; OR 1.40,
CI95 1.13–1.75) and age (per year; OR 1.10, CI95 1.02–
1.19).

Discussion
To better understand the epidemiology of CDAD infection in critically ill patients, we investigated its clinical
course and outcome in the intensive care units of a tertiary
care, academic medical center. Of the 58 ICU patients
with C. difficile colitis in our cohort study, a significant
proportion of these patients had concurrent infection
(62.1%). The majority of the pathogens associated with
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nosocomial infections in our study cohort were gastrointestinal flora. This finding coupled with the relatively high
proportion of bloodstream infections that were polymicrobial suggest that the inflammation and disruption
of the colonic mucosa by CDAD provided a source of
entry for organisms into the bloodstream. Of note, 60%
of these patients had recently been treated with antimicrobials with significant activity against anaerobes, suggesting an important protective role that anaerobes may play
in the intestinal flora. Similarly, disruption of the anaerobic gut flora has been shown to be a risk factor for VRE colonization [18], an epidemiologic finding that has been
experimentally validated in an animal model [19].
As more than a half of our C. difficile patients were coinfected, findings predictably showed that a high proportion of ICU CDAD patients had a maximal SIR (severe
sepsis, septic shock or death) during 14 days of follow-up.
However, no statistically difference was observed in maximal SIR between patients with CDAD only those with
CDAD and another infection (p = 0.17). One potential
explanation for this observation may have been the delay
in the introduction of specific antimicrobial therapy (metronidazole or oral vancomycin) for patients with CDAD.
In our study, ICU patients were symptomatic with
diarrhea on average for 6.5 days prior to microbiologic
confirmation of the CDAD diagnosis and initiation of
therapy. In our study cohort, no patients required surgical
procedures as a result of CDAD. This is similar to another
report in which 2.5% of patients required emergency
colectomy [20].
Some studies have shown that treatment of CDAD with
metronidazole may lead to poor outcomes [21,22]. In our
study it was not our purpose to determine the efficacy of
metronidazole since we had multiple confounders such as
a high rate of co-infection, and some patients died before

Table 2: Univariate analysis of risk factors for in-hospital mortality in CDAD patients.

Died (n = 16)
VARIABLES
Age, median years (IQR)
Male
Charlson ≥3
SOFA score at infection onset, median (IQR)
Other infections concurrently
Days of diarrhea prior to positive C. difficile toxin assay, median (IQR)
Organ failure (any)
Septic shock
Respiratory failure
Renal failure
Hematologic failure
Hepatic failure

Recovered (n = 42)

N

%

N

%

61.0 (56.0–69.0)
7
5
9.5 (6.0–14.5)
11
7.5 (2.0–14.2)
16
12
14
11
3
5

43.8
31.3
68.8
100.0
75.0
87.5
68.8
18.8
31.3

53.0 (36.7–63.0)
28
12
4.0 (2.0–6.0)
25
3.0 (2.0–7.0)
28
7
22
6
3
3

66.7
28.6
59.5
66.7
16.7
52.4
14.3
7.1
7.1

P

0.015
0.11
1.0
<0.001
0.52
0.32
0.01
<0.001
0.014
<0.001
0.33
0.03

IQR, Inter-quartile range
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Table 3: Multivariate analysis of factors independently associated
with death in ICU patients with CDAD.

VARIABLES

OR

95%CI

P

Age, years (per 1-year increment)
SOFA score at infection onset (per
1-point increment)
Organ failure (any)*

1.10
1.40

1.02–1.19
1.13–1.75

0.011
0.002

-

-

0.998

#Hosmer and Lemeshow goodness-of-fit statistic = 7.1 (8 DF) (p =
0.53)
OR, odds ratio
CI, confidence interval
*Organ failure occurred in 100% who died from CDAD, as such,
there is no odds ratio and confidence interval

completing metronidazole treatment. Almost one-fifth of
our patients received antibiotics in the absence of evidence to suggest a concurrent infection. This observation
is particularly important as prior reports suggest that
unnecessary antibiotic use makes treatment of CDAD
more difficult and potentially less efficacious [2,3].

nosocomial co-infection. As such, the management of
these infections remains challenging. In ICU patients with
CDAD, advanced age and increased severity of illness at
the onset of infection, as measured by the SOFA score, are
independent predictors of death.

Key messages
CDAD is not an infrequent infection with an usually late
diagnosis and therapy, and high potential comorbidity
and mortality. Almost one-fifth of our patients received
antibiotics in the absence of evidence to suggest a concurrent infection. Antibiotics are used in a indiscriminate way
in ICU. This observation is particularly important as prior
reports suggest that unnecessary antibiotic use makes
treatment of CDAD more difficult and potentially less
efficacious.
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advanced age (≥65 years) is a risk factor for recurrence of
CDAD following treatment with metronidazole. By multivariate analysis, we demonstrated that for ICU patients
with CDAD, advanced age and a high SOFA score were
independent predictors of mortality. Prior studies have
identified advanced age as a risk factor for CDAD [11,24].
To our knowledge, no other studies have reported SOFA
score as a predictor for mortality in ICU patients with
CDAD.
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